Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by University Hospital, Angers.
Recruitment status was  Recruiting
Information provided by:
University Hospital, Angers Identifier:
First received: September 8, 2005
Last updated: March 16, 2007
Last verified: March 2007

Microvascular dysfunctions are critical events in several diseases including diabetes. This study will develop a methodology for microvascular investigation in human skin. The purpose of the study is to investigate the physiological response of the cutaneous microcirculation to physical, thermal, mechanical or chemical stimulations.

Condition Intervention Phase
Healthy Volunteers
Device: pressure strain system, iontophoresis
Drug: scopolamin
Drug: emla
Drug: capsaicin
Drug: aspirin
Drug: clopidogrel
Drug: celecoxib
Drug: indomethacin
Drug: acetylcholine
Drug: sodium nitroprusside
Drug: brethyllium
Device: general and local heating
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Diagnostic
Official Title: Etude de la Reserve Vasomotrice Microcirculatoire cutanée

Resource links provided by NLM:

Further study details as provided by University Hospital, Angers:

Primary Outcome Measures:
  • Amplitude of the vasomotor response to stimuli

Secondary Outcome Measures:
  • Kinetics of the vasomotor response to stimuli

Estimated Enrollment: 85
Study Start Date: January 1996
Estimated Study Completion Date: January 2008
Detailed Description:

This study has investigated various aspects of the physiology of the microcirculation in the past years and is still recruiting under parallel protocols of physiological investigations of the neurovascular control of the cutaneous microcirculation.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers with no clinical signs of, or risk factors for, vascular disease

Exclusion Criteria:

  • Smokers, Pregnancy, Allergy,
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00152724

Contact: Pierre ABRAHAM, MD, PhD (0)2-41-35-46-17 ext 33

Laboratoire de Physiologie et Explorations Vasculaires - CHU Angers Recruiting
Angers, France, 49033
Contact: Pierre ABRAHAM, MD, PhD    (0)2-41-35-46-17 ext 33   
Sponsors and Collaborators
University Hospital, Angers
Principal Investigator: Jean Louis SAUMET, MD - PhD University Hospital, Angers
  More Information

Publications: Identifier: NCT00152724     History of Changes
Other Study ID Numbers: CP96-04
Study First Received: September 8, 2005
Last Updated: March 16, 2007
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Angers:
Laser-Doppler Flowmetry

Additional relevant MeSH terms:
Antihypertensive Agents
Cardiovascular Agents
Cholinergic Agents
Cholinergic Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nitric Oxide Donors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents processed this record on October 06, 2015